Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
uniQure Announces Pricing of its Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing...
uniQure Announces Proposed Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative...
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease ~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing...
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy LEXINGTON, Mass. and AMSTERDAM, Nov. 21...
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress ~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions...
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V...
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a...
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure...
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update ~ Announced RMAT designation for AMT-130 in Huntington’s disease and positive interim Phase I/II data...
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen ~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.085 | -0.621118012422 | 13.685 | 14 | 12.605 | 256 | 13.27095628 | DE |
| 4 | -2.53 | -15.6850588965 | 16.13 | 18.38 | 12.605 | 431 | 16.15892147 | DE |
| 12 | 7.586 | 126.139008979 | 6.014 | 18.38 | 5.24 | 1652 | 13.25700078 | DE |
| 26 | 6.648 | 95.6271576525 | 6.952 | 18.38 | 4.11 | 1153 | 11.01398132 | DE |
| 52 | 8.44 | 163.565891473 | 5.16 | 18.38 | 3.548 | 1253 | 8.66595332 | DE |
| 156 | -3.42 | -20.0940070505 | 17.02 | 25.61 | 3.548 | 868 | 8.60094039 | DE |
| 260 | -17.86 | -56.770502225 | 31.46 | 32.78 | 3.548 | 578 | 9.7823537 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
